Progress of Angiogenesis Signal Pathway and Antiangiogenic Drugs in Nasopharyngeal Carcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Nasopharyngeal cancer, often diagnosed late, can be treated with antiangiogenic drugs. This review covers their mechanisms and potential new therapeutic targets for this rare cancer.
Area Of Science
- Oncology
- Cancer Biology
- Pharmacology
Background
- Nasopharyngeal cancer (NPC) is a rare malignancy with distinct geographic and ethnic prevalence.
- Early NPC symptoms are often subtle, leading to diagnosis at advanced stages.
- NPC is prone to recurrence and distant metastasis, necessitating effective treatment strategies.
Purpose Of The Study
- To review the current research on antiangiogenic drugs for nasopharyngeal cancer.
- To elucidate the mechanisms of action of these antiangiogenic therapies.
- To identify and propose novel antiangiogenic therapeutic targets for NPC.
Main Methods
- Literature review of recent studies on antiangiogenic therapies for NPC.
- Analysis of the molecular mechanisms underlying angiogenesis in NPC.
- Evaluation of the efficacy and limitations of current antiangiogenic treatments.
Main Results
- Antiangiogenic therapy has shown significant promise in treating advanced NPC.
- Understanding angiogenesis is crucial for developing targeted treatments.
- Several novel therapeutic targets for antiangiogenic strategies in NPC are emerging.
Conclusions
- Antiangiogenic drugs represent a key treatment modality for nasopharyngeal cancer.
- Further research into novel targets and combination therapies is warranted.
- Targeting angiogenesis offers a promising avenue for improving outcomes in NPC patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...